Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 5/20 | 0.89 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.89 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.89 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.89 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.89 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.89 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.89 |
| ▸ | RHOC | P08134 | 1/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.89 |
| ▸ | THRB | P10828 | 1/20 | 0.89 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.89 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.89 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.86 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.86 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.86 |
| ▸ | PDE6D | O43924 | 4/20 | 0.76 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.57 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14434996 | 1.00 | HMGCR (0.89) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL14130942 | 1.00 | HMGCR (0.89) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL14605733 | 0.96 | HMGCR (0.81) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL13412147 | 0.94 | HMGCR (0.79) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL8348165 | 0.94 | HMGCR (0.79) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL14107531 | 0.94 | HMGCR (0.79) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL3056792 | 0.94 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL21637576 | 0.94 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL4201645 | 0.94 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL13900412 | 0.94 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172857-B2 | Boosting the effect of methotrexate through the combined use with lipophilic statins | DALANA3, S.L. (ES) | 2019-01-08 | — | — | US | disclosed |
| US-20180002297-A1 | Tetrazolones as a Carboxylic Acid Bioisosteres | MIDCAP FINANCIAL TRUST | 2018-01-04 | — | — | US | disclosed |
| US-9701647-B2 | Tetrazolones as a carboxylic acid bioisosteres | RIGEL PHARMACEUTICALS, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170129862-A1 | Tetrazolones as a Carboxylic Acid Bioisosteres | MIDCAP FINANCIAL TRUST | 2017-05-11 | — | — | US | disclosed |
| US-9439888-B2 | Tetrazolones as a carboxylic acid bioisosteres | RIGEL PHARMACEUTICALS, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20160213648-A1 | Tetrazolones as a Carboxylic Acid Bioisosteres | MIDCAP FINANCIAL TRUST | 2016-07-28 | — | — | US | disclosed |
| US-20160015819-A1 | FATTY ACID CONJUGATES OF STATIN AND FXR AGONISTS: COMPOSITIONS AND METHODS OF USE | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-9084826-B2 | Fatty acid conjugates of statin and FXR agonists; compositions and method of uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150133390-A1 | Identification of New Therapeutic Uses for Known Therapeutic Agents | National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Govt. (US) | 2015-05-14 | — | — | US | disclosed |
| US-8828438-B2 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase | BEND RESEARCH, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-7812179-B2 | Process for the preparation of atorvastatin and intermediates | APOTEX PHARMACHEM INC. (CA) | 2010-10-12 | — | — | US | disclosed |
| US-7615647-B2 | Process for producing atorvastatin hemicalcium | APOTEX PHARMACHEM INC. (CA) | 2009-11-10 | — | — | US | disclosed |
| US-20090216029-A1 | PROCESS FOR THE PRODUCTION OF ATORVASTATIN CALCIUM IN AMORPHOUS FORM | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | disclosed |
| US-20090131683-A1 | Process for the preparation of atorvastatin and intermediates | APOTEX PHARMACHEM INC. | 2009-05-21 | — | — | US | disclosed |
| US-20090118328-A1 | Pharmaceutical Compositions Of Cholesteryl Ester Transfer Protein Inhibitors And Hmg-Coa Reductase | BEND RESEARCH, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-20080262074-A1 | Salt Forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methylethyl)-3-(Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid | PFIZER, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-7429613-B2 | Process for the preparation of atorvastatin and intermediates | APOTEX PHARMACHEM INC. (CA) | 2008-09-30 | — | — | US | disclosed |
| US-7193090-B2 | Preparation of atorvastatin | APOTEX PHARMACHEM INC. (CA) | 2007-03-20 | — | — | US | disclosed |
| US-20070032664-A1 | Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide | BUTLER DONALD E | 2007-02-08 | — | — | US | disclosed |
| US-20070032664-A1 | Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide | BUTLER DONALD E | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131683-A1 | Process for the preparation of atorvastatin and intermediates | ACSL1, ACSL3, ACSL6 | HMGCR 5/4885SLCO1B1 685/4885ABCB11 1442/4885 |
| US-20090216029-A1 | PROCESS FOR THE PRODUCTION OF ATORVASTATIN CALCIUM IN AMORPHOUS FORM | HMGCR, CACYBP, SARAF | HMGCR 1/4885SLCO1B1 433/4885ABCB11 2194/4885 |
| US-20090118328-A1 | Pharmaceutical Compositions Of Cholesteryl Ester Transfer Protein Inhibitors And Hmg-Coa Reductase | CETP, HMGCR, MTTP | HMGCR 2/4885SLCO1B1 114/4885ABCB11 78/4885 |
| US-20170129862-A1 | Tetrazolones as a Carboxylic Acid Bioisosteres | GLS, CYP11B2, GLS2 | HMGCR 823/4885SLCO1B1 707/4885ABCB11 331/4885 |
| US-20070032664-A1 | Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide | PAH, PCCA, HPD | HMGCR 1030/4885SLCO1B1 4058/4885ABCB11 4824/4885 |
| US-10172857-B2 | Boosting the effect of methotrexate through the combined use with lipophilic statins | DHFR, TPMT, HMGCR | HMGCR 3/4885SLCO1B1 589/4885ABCB11 1532/4885 |
| US-20150133390-A1 | Identification of New Therapeutic Uses for Known Therapeutic Agents | CD74, SERPINA6, ANXA4 | HMGCR 1173/4885SLCO1B1 4747/4885ABCB11 3191/4885 |
| US-20160015819-A1 | FATTY ACID CONJUGATES OF STATIN AND FXR AGONISTS: COMPOSITIONS AND METHODS OF USE | SLC10A1, NR1H4, FXR1 | HMGCR 11/4885SLCO1B1 209/4885ABCB11 70/4885 |
| US-20080262074-A1 | Salt Forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methylethyl)-3-(Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid | BPHL, HMGCR, GRHPR | HMGCR 2/4885SLCO1B1 1366/4885ABCB11 1243/4885 |
| US-20160213648-A1 | Tetrazolones as a Carboxylic Acid Bioisosteres | GLS, CYP11B2, GLS2 | HMGCR 823/4885SLCO1B1 707/4885ABCB11 331/4885 |
| US-20180002297-A1 | Tetrazolones as a Carboxylic Acid Bioisosteres | GLS, CYP11B2, GLS2 | HMGCR 823/4885SLCO1B1 707/4885ABCB11 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.